Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Fuji
Farmers Insurance
Julphar
Cantor Fitzgerald
Dow
Merck
McKesson
Daiichi Sankyo
Queensland Health

Generated: January 18, 2018

DrugPatentWatch Database Preview

VOGELXO Drug Profile

« Back to Dashboard

Which patents cover Vogelxo, and what generic alternatives are available?

Vogelxo is a drug marketed by Upsher-smith Labs and is included in one NDA. There are three patents protecting this drug.

This drug has seven patent family members in seven countries.

The generic ingredient in VOGELXO is testosterone. There are sixty-three drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.
Summary for VOGELXO
Drug patent expirations by year for VOGELXO
Pharmacology for VOGELXO
Ingredient-typeAndrostanes
Drug ClassAndrogen
Mechanism of ActionAndrogen Receptor Agonists
Medical Subject Heading (MeSH) Categories for VOGELXO

US Patents and Regulatory Information for VOGELXO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upsher-smith Labs VOGELXO testosterone GEL, METERED;TRANSDERMAL 204399-003 Jun 4, 2014 BX RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Upsher-smith Labs VOGELXO testosterone GEL;TRANSDERMAL 204399-002 Jun 4, 2014 AB2 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Upsher-smith Labs VOGELXO testosterone GEL, METERED;TRANSDERMAL 204399-003 Jun 4, 2014 BX RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Upsher-smith Labs VOGELXO testosterone GEL;TRANSDERMAL 204399-002 Jun 4, 2014 AB2 RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Upsher-smith Labs VOGELXO testosterone GEL, METERED;TRANSDERMAL 204399-003 Jun 4, 2014 BX RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Upsher-smith Labs VOGELXO testosterone GEL, METERED;TRANSDERMAL 204399-003 Jun 4, 2014 BX RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Upsher-smith Labs VOGELXO testosterone GEL;TRANSDERMAL 204399-002 Jun 4, 2014 AB2 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Upsher-smith Labs VOGELXO testosterone GEL;TRANSDERMAL 204399-002 Jun 4, 2014 AB2 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Fuji
Citi
Queensland Health
Covington
UBS
Cantor Fitzgerald
Chinese Patent Office
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot